AIIA collaborates with Nisarga Herbs to conduct India’s first clinical trial on prevention of Covid-19 with Neem capsules
All India Institute of Ayurveda, New Delhi has announced their collaboration with Nisarga Biotech Pvt Ltd, parent company of Nisarga Herbs to conduct a double-blind, randomised, placebo controlled trial at ESIC Medical College and Hospital, Faridabad. Prof. (Dr.) Tanuja Nesari, MD, PhD, Director of AIIA, will be the Principal Investigator and Dr. Asim Sen, Dean ESIC medical college and hospital, Faridabad will be the co-investigator along with team of 6 doctors from AIIA and ESIC. Nisarga is the first Indian Ayurveda company to work with AIIA, who will study their proprietary neem extract formulation for the prevention of Covid-19 in 250 subjects. The study entitled ‘Prophylaxis with Neem Capsules (Azadirachta Indica) in Healthcare Personnel and Relatives in Contact with COVID-19 Patients’ is designed primarily to evaluate the preventative effect of neem capsules in subjects coming in contact with COVID- 19 patients.
The first step of recruitment for this Human trials has already started from 7th August wherein the formulation will be tested and studied on 250 individuals and this would be a double-blind trial where 125 patients would be using their proprietary Neem capsules while the other 125 would be taking blank capsules for 28 days. The drug will be administered for 28 days followed by the observation period of 28 days and check the effect of the capsules in comparison with the blank capsules. Neem formulation is the proprietary Ayurvedic formulation from Nisarga’s robust pipeline. Nisarga Herbs is marketing products in India and with multiple distribution partners overseas as well.